Navigation Links
Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Date:4/9/2009

THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER JOINS PHASE III TRIAL FOR METASTATIC MELANOMA

NEW YORK, April 9 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute has joined Delcath's Phase III clinical trial for the treatment of metastatic melanoma in the liver. Ohio State is the twelfth center to join this multi-center trial testing the Company's Percutaneous Hepatic Perfusion (PHP(TM)) System for the isolated, high-dose delivery of the anti-cancer agent melphalan.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

Delcath and Ohio State have entered into a clinical research agreement to conduct the Phase III National Cancer Institute (NCI) led study. Dr. Mark Bloomston, a surgical oncologist specializing in regional cancer therapy, will serve as the Principal Investigator. Commenting on joining this trial, Dr. Bloomston stated, "The Delcath PHP System(TM) is a welcome addition to the currently available therapies for liver cancer, and we look forward to treating patients in this trial. Metastatic melanoma, once it reaches the liver, has few viable treatment options. This technology offers a very promising approach for targeting the disease in the liver and we are eager to provide this modality to our patients."

Commenting on this twelfth center joining the trial, Richard L. Taney, President and CEO of Delcath, stated, "We are delighted to have Ohio State and Dr. Bloomston join this trial as we continue to expand to an increasing number of leading cancer centers in the United States. The prestige of these centers is a validation of the need for a viable treatment option for these very ill patients. Continuing to expand this trial assists in the acceleration of enrollment, increases the awareness of the Delcath PHP System(TM) among physicians, and expands patient access to PHP(TM)."

About The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute is one of only 40 NCI-designated Comprehensive Cancer Centers in the United States and the only freestanding cancer hospital in the Midwest. Ranked among the top 20 cancer hospitals in the nation, The James is the 172-bed adult patient-care component of the cancer program at The Ohio State University. For more information, visit www.jamesline.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
2. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
3. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
4. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
5. Vantia Therapeutics Pipeline Continues to Mature
6. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
7. ACORN Continues Success in Oncology Data Warehousing With Accumulation of Nearly 50 Million Data Observations
8. AlphaVax Continues to Expand the Use of Its Vaccine Platform
9. Replidyne Discontinues Phase III Trial
10. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
11. Medarex Announces Ipilimumab Program Continues to Move Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):